Vanda Pharmaceuticals (VNDA) Stock Soars After FDA Approves BYSANTI for Bipolar I and Schizophrenia 
Medicare to Cover GLP-1 Weight-Loss and Diabetes Drugs Starting July 1 
Takeda Hit With $885M Verdict Over Amitiza Generic Drug Delay Scheme 
TrumpRx Expands Discount Drug Access With 600 Generic Medications 
RFK Jr. Faces Scrutiny Over David Geier’s HHS Role and Vaccine Review Work 
OpenAI Wins Elon Musk Lawsuit as Jury Rejects Claims Over AI Mission 
Supreme Court Blocks 5th Circuit Ruling on Abortion Pill Access 
Why the future of marijuana legalization remains hazy despite high public support 
Tencent Shares Jump 4% as AI Models Move Toward Paid Commercial Services 
Google, Blackstone Launch $5B AI Cloud Venture to Challenge Nvidia and CoreWeave 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Mistral AI Acquires Emmi AI to Expand Industrial AI Solutions in Europe 
Standard Chartered Appoints Manus Costello as New CFO Amid Leadership Reshuffle 
AstraZeneca reported robust first-quarter 2026 earnings, driven by strong demand for its oncology and rare disease treatments, delivering solid revenue growth and beating analyst expectations. The U.K.-based pharmaceutical giant posted total revenue of $15.29 billion, up from $13.59 billion in the same period last year and above the consensus estimate of $14.94 billion. On a constant currency basis, revenue increased 8% year-over-year, highlighting sustained global demand across its core therapeutic areas.
The company’s oncology portfolio remained a key growth engine, with sales rising 16% year-over-year at constant currency to $6.8 billion. This segment now contributes approximately 44% of AstraZeneca’s total revenue, underscoring its strategic importance. Several flagship cancer drugs delivered notable performance, including Imfinzi, which surged 30% to $1.7 billion, and Enhertu, which jumped 34% to $831 million. Tagrisso, another leading lung cancer therapy, also posted growth, increasing 5% to $1.8 billion.
Core earnings per share (EPS), a key profitability metric that excludes one-off items, came in at $2.58, surpassing analyst forecasts of $2.54 and marking a 5% increase at constant currency. Core operating profit rose 12% to $4.25 billion, reflecting improved operational efficiency and continued investment in commercial capabilities. Meanwhile, net profit climbed to $3.08 billion from $2.92 billion a year earlier.
CEO Pascal Soriot emphasized the company’s strong commercial execution and ongoing investments, noting that AstraZeneca is well-positioned for multiple upcoming product launches and clinical readouts in 2026. The company reiterated its full-year guidance, expecting revenue growth in the mid-to-high single-digit range and core EPS growth in the low double digits.
With continued momentum in its oncology pipeline and expanding rare disease portfolio, AstraZeneca remains a major player in the global pharmaceutical market, attracting investor attention as it works toward its long-term growth ambitions through 2030 and beyond.
